DrugLogic(R), Inc. Announces Availability and Pilot Program of Qscan(R)-VAERS.RESTON, Va. -- DrugLogic(R), Inc. is pleased to announce the release into production of Qscan(R)-VAERS. This latest member of the Qscan(R) family is the first subscription offering of the Vaccine Adverse Event Reporting System The Vaccine Adverse Event Reporting System is a United States program for vaccine safety, co-sponsored by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). , Qscan(R)-VAERS is released with the Version 3.2 multiple database version of the core Qscan(R) system. It will allow users' comparisons of VAERS VAERS Vaccine Adverse Event Reporting System (lists hospitalizations or deaths resulting from vaccinations) data with the post market vaccine adverse event data as reported in the freedom of information AERS AERS Adverse Event Reporting System (database of drug adverse reactions) AERS Association of Educators in Radiological Sciences AERS Army Educational Requirements System AERS Acute Equine Respiratory Syndrome AERS Access/Egress Roadway System data of the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. . Current subscribers to Qscan(R)-FDA will have a 30 day pilot period to experience both the VAERS database benefits and multiple database features of Qscan(R) 3.2. A subscription will be offered at the end of the period for a nominal additional charge. Qscan(R)-VAERS incorporates the drug safety research tools that have been improving for the past six years. As with other public data sharing The ability to share the same data resource with multiple applications or users. It implies that the data are stored in one or more servers in the network and that there is some software locking mechanism that prevents the same set of data from being changed by two people at the same time. similar reaction dictionaries such as MedDRA (R), Qscan(R) -VAERS integrates seamlessly and quickly with existing adverse event data-capture systems, and with clinical data management systems to allow cross comparisons and proportional analysis. "Vaccine safety involves the extra dimension of protection for our younger population," says Victor Gogolak, President of DrugLogic(R). "Vaccine companies are anxious to view simultaneously various sources of data, and DrugLogic is committed to supporting them." Qscan(R)-VAERS will incorporate all of the features of the recently released multiple database version 3.2 of Qscan(R). This will allow the vaccines data in both the VAERS and AQERS systems to be analyzed an·a·lyze tr.v. an·a·lyzed, an·a·lyz·ing, an·a·lyz·es 1. To examine methodically by separating into parts and studying their interrelations. 2. Chemistry To make a chemical analysis of. 3. and cross-compared. The proportional analysis, multiple background and custom background features will offer researchers unprecedented flexibility. In addition, the different perspectives of the reporting systems can be accounted for. About DrugLogic(R), Inc. DrugLogic(R), Inc. specializes in developing analytical analytical, analytic pertaining to or emanating from analysis. analytical control control of confounding by analysis of the results of a trial or test. tools and enterprise process support systems for managing risks related to drug safety issues. DrugLogic is dedicated to designing, developing and delivering products that provide the latest innovations and state-of-the art solutions in support of pharmacovigilance and drug safety surveillance practices for both pharmaceutical and biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. companies. Its proprietary and patented Qscan(R) product line both analyzes and monitors company internal adverse event data and publicly available data sources. For more information, visit www.druglogic.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion